We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

124 hedge funds and large institutions have $378M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 20

95% more capital invested

Capital invested by funds: $194M → $378M (+$184M)

19% more funds holding

Funds holding: 104 → 124 (+20)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 32

81% less call options, than puts

Call options by funds: $596K | Put options by funds: $3.22M

Holders
124
Holders Change
+20
Holders Change %
+19.23%
% of All Funds
2.18%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
40
Increased
32
Reduced
32
Closed
20
Calls
$596K
Puts
$3.22M
Net Calls
-$2.63M
Net Calls Change
-$2.25M

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$35.7M
2
Victory Capital Management
Victory Capital Management
Texas
+$25.7M
3
O
OrbiMed
New York
+$20M
4
CCM
CAAS Capital Management
New York
+$11.5M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.5M

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP II
Massachusetts
-$29.6M
2
WP
Woodline Partners
California
-$6.59M
3
SI
Sofinnova Investments
California
-$4.53M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$1.53M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
126
Dupont Capital Management
Delaware
– -$244K -34,893 Closed
GCP
127
GSA Capital Partners
United Kingdom
– -$215K -30,696 Closed
GTCM
128
Gyon Technologies Capital Management
New Jersey
– -$188K -26,893 Closed
OPERF
129
Oregon Public Employees Retirement Fund
Oregon
– -$176K -25,166 Closed
TI
130
Trexquant Investment
Connecticut
– -$169K -24,204 Closed
EGM
131
Engineers Gate Manager
New York
– -$100K -14,300 Closed
Arrowstreet Capital
132
Arrowstreet Capital
Massachusetts
– -$96K -13,728 Closed
Invesco
133
Invesco
Georgia
– -$89K -12,792 Closed
WG
134
Winton Group
United Kingdom
– -$81K -11,585 Closed
PCM
135
Parsons Capital Management
Rhode Island
– -$76K -10,816 Closed
JF
136
Jump Financial
Illinois
– -$72K -10,300 Closed
Ohio Public Employees Retirement System (OPERS)
137
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$50K -7,088 Closed
Simplex Trading
138
Simplex Trading
Illinois
– -$23.7K -2,166 Closed
ASN
139
Advisory Services Network
Georgia
– -$1K -81 Closed
CS
140
Candriam SCA
Luxembourg
– +$55 +5 New
HI
141
Harbour Investments
Wisconsin
– +$515 +47 New
2 3 4 5
6

JNCE Hedge Fund Activity: Q1 2021 in Review

124 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2021, worth a combined $378M — up 95% from $194M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new JNCE positions and 20 closed out — a net gain of 20 holders — while 32 added to existing stakes and 32 trimmed.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $35.7M. The largest seller was TRV GP II, cutting an estimated $29.6M.

  • 124 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2021, up from 104 in Q4 2020.
  • Funds reported $378M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2021, up 95% quarter-over-quarter.
  • 40 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2021 and 20 closed out, a net change of +20 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2021 was PFM Health Sciences, an estimated $35.7M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2021 was TRV GP II, an estimated $29.6M sold.

Based on aggregated 13F filings for Q1 2021.